NCT04005365Unknown2 期
Efficacy and Safety of Propranolol Combined With Neoadjuvant Chemotherapy in Stage III-IV Gastric Cancer: an Open-lable, Single-arm Study
Yijing He1 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2019年11月20日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 78
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
At the cellular and animal level, we found that propranolol can inhibit the proliferation and invasion of gastric cancer cells. Further, we want to explore the efficacy and safety of propranolol in the treatment of gastric cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must provide written informed consent.
- •age 18 to 75;Confirmed as a primary gastric adenocarcinoma patient by imaging and histology or cytology;
- •Patients with advanced gastrointestinal cancer who have received no prior chemotherapy or radiotherapy for malignant tumors;
- •Patients with Eastern Cooperative Oncology Group Performance Status of 0 or
- •Patients with a life expectancy of at least three months.;
- •Organ function and hematopoietic function must meet the following requirements: hemoglobin (HGB) ≥ 90g / L; white blood cell count (WBC) ≥ 3 × 10 ^ 9 / L; absolute neutrophil count (ANC) ≥ 1.5 × 10 ^ 9 / L Platelet count (PLT) ≥ 100 × 10 ^ 9 / L; total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase ( ALT)≤2.5×ULN; if abnormal liver function is due to tumor liver metastasis, AST or ALT≤5×ULN; serum creatinine (Cr)≤1.5×ULN; international normalized ratio (INR) or plasma prothrombin time ( PT) ≤ 1.5 × ULN.
- •Systolic blood pressure 90-140mmHg, diastolic blood pressure 60-90mmHg, heart rate 60-100bpm.
- •No previous cardiovascular and cerebrovascular diseases, and exclusion of atrioventricular block by 24-hour ambulatory electrocardiography;
- •subjects must agree to take effective contraceptive measures between the subject and the partner after signing the informed consent, during the study period and within 5 months after the last dose.
排除标准
- •There are clinical symptoms or diseases of the heart that are not well controlled, such as uncontrolled high blood pressure, unstable angina, or myocardial infarction within 6 months prior to enrollment, or poorly controlled arrhythmias (including QTc ( men ≥ 450ms , female ≥ 470ms, QTc interval calculated by Fridericia formula), cardiogenic shock, heart block (II-III degree atrioventricular block), severe or acute heart failure, sinus bradycardia, need continuous oxygen Treated severe respiratory diseases;
- •Subjects with symptomatic autoimmune diseases [such as, but not limited to, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, decreased thyroid function; The tester has vitiligo or has completely relieved asthma in childhood, and can be included without any intervention after adulthood; asthma that requires bronchodilators for medical intervention cannot be included]
- •Patients with other malignant tumors within 5 years prior to enrollment, in addition to appropriate treatment of cervical carcinoma in situ, cured skin basal cell carcinoma;
- •Immunodeficiency, such as a patient with HIV infection or other acquired, congenital immunodeficiency disease, or a history of organ transplantation
- •Patients with active tuberculosis infection by medical history or CT examination, or a history of active tuberculosis infection within 1 year prior to enrollment, or patients with a history of active tuberculosis infection more than 1 year without formal treatment;
- •Patients with tumor brain metastasis and bone marrow metastasis
- •Patients who participated in other drug clinical studies within 4 weeks;
- •Patients with history of hypersensitivity to any drugs in this study;
- •Identified as neurological or psychiatric disorders, such as epilepsy, dementia, poor compliance;
- •Alcohol abuse, drug abuse in the past year;
- •Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA (HBV DNA) > 10 ^ 3 copies / mL, or hepatitis C virus antibody positive; syphilis positive;
- •Subjects had active infection or unexplained fever >38.5 degrees during Screening period before the first dose (according to the researcher, the subject can be enrolled due to fever generated by the tumor.);
- •Clinical symptoms of ascites or pleural effusion, requiring therapeutic puncture or drainage;
- •Female patients who are pregnant or lactating, or planning to become pregnant or lactating;
- •Other patients who are considered to be unsuitable for this study by the investigator.
研究组 & 干预措施
Prop+neochemo
Experimental
干预措施: Propranolol (Drug)
结局指标
主要结局
ORR
时间窗: Preoperative assessment
CR+PR
次要结局
未报告次要终点
研究者
Yijing He
Associate Professor
Central South University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
to evaluate Efficacy and Safety of oral Propranolol in enlarging Hemangioma in children less than one year.CTRI/2013/09/003975GCS Medical College and research centre
Unknown
2 期
a Prospective Cohort Study for Propranolol Treatment in Retinopathy of PrematurityRetinopathy of PrematurityNCT03038295Guangdong Women and Children Hospital100
已完成
2 期
Safety and Efficacy of Propranolol in Newborns With Retinopathy of PrematurityRetinopathy of PrematurityNCT01079715Azienda Ospedaliero, Universitaria Meyer52
尚未招募
1 期
Propranolol Adjuvant Treatment of Focal Refractory Epilepsy (PATFRE)Epilepsy, Drug ResistantNCT06719804Xuanwu Hospital, Beijing15
Unknown
1 期
Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO)AngiosarcomaNCT02732678Assistance Publique Hopitaux De Marseille24